# REPRINT (NCT06302569)

> Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06302569
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Giuseppe Procopio
- Conditions: Bellini Carcinoma; Collecting Duct Carcinoma; Renal Medullary Carcinoma
- Interventions: Pembrolizumab + Enfortumab Vedotin
- Enrollment: 23
- Primary outcome: ORR in patients treated with Pembrolizumab plus Enfortumab Vedotin

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=reprint-nct06302569